化学療法誘発性好中球減少症治療薬の世界市場（～2026年）

• 英文タイトル：Global Chemotherapy Induced Neutropenia Drug Market Insights and Forecast to 2026

• レポートコード：MRC2-11QY00178 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、188ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料は化学療法誘発性好中球減少症治療薬のグローバル市場について調査・分析したレポートです。種類別（F-627、BBT-018、フィルグラスチム、GW-003、NLA-101、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別化学療法誘発性好中球減少症治療薬の競争状況、市場シェア ・世界の化学療法誘発性好中球減少症治療薬市場：種類別市場規模 2015年-2020年（F-627、BBT-018、フィルグラスチム、GW-003、NLA-101、その他） ・世界の化学療法誘発性好中球減少症治療薬市場：種類別市場規模予測 2021年-2026年（F-627、BBT-018、フィルグラスチム、GW-003、NLA-101、その他） ・世界の化学療法誘発性好中球減少症治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界の化学療法誘発性好中球減少症治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米の化学療法誘発性好中球減少症治療薬市場分析：米国、カナダ ・ヨーロッパの化学療法誘発性好中球減少症治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの化学療法誘発性好中球減少症治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の化学療法誘発性好中球減少症治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの化学療法誘発性好中球減少症治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：BeyondSpring Pharmaceuticals Inc、Biocon Ltd、Bolder Biotechnology Inc、Cellerant Therapeutics Inc、Chong Kun Dang Pharmaceutical Corp、Cinfa Biotech SL、Dr. Reddy's Laboratories Ltd、Gene Techno Science Co Ltd、Generon (Shanghai) Corp Ltd、Genexine Inc、GlycoMimetics Inc、Hanmi Pharmaceuticals Co Ltd、Intas Pharmaceuticals Ltd、Lupin Ltd、Mycenax Biotech Inc、Myelo Therapeutics GmbH、Nohla Therapeutics Inc、Octapharma AG、Pangen Biotech Inc.、Pfenex Inc、Pfizer Inc、Reliance Life Sciences Pvt Ltd、Richter Gedeon Nyrt、Sandoz International GmbH、USV Pvt Ltd ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

Market Analysis and Insights: Global Chemotherapy Induced Neutropenia Drug Market
The global Chemotherapy Induced Neutropenia Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Chemotherapy Induced Neutropenia Drug Scope and Market Size
Chemotherapy Induced Neutropenia Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Chemotherapy Induced Neutropenia Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Chemotherapy Induced Neutropenia Drug market is segmented into
F-627
BBT-018
Filgrastim
GW-003
NLA-101
Others

Segment by Application, the Chemotherapy Induced Neutropenia Drug market is segmented into
Hospital
Clinic
Others

Regional and Country-level Analysis
The Chemotherapy Induced Neutropenia Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Chemotherapy Induced Neutropenia Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Chemotherapy Induced Neutropenia Drug Market Share Analysis
Chemotherapy Induced Neutropenia Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Chemotherapy Induced Neutropenia Drug business, the date to enter into the Chemotherapy Induced Neutropenia Drug market, Chemotherapy Induced Neutropenia Drug product introduction, recent developments, etc.

The major vendors covered:
BeyondSpring Pharmaceuticals Inc
Biocon Ltd
Bolder Biotechnology Inc
Cellerant Therapeutics Inc
Chong Kun Dang Pharmaceutical Corp
Cinfa Biotech SL
Dr. Reddy’s Laboratories Ltd
Gene Techno Science Co Ltd
Generon (Shanghai) Corp Ltd
Genexine Inc
GlycoMimetics Inc
Hanmi Pharmaceuticals Co Ltd
Intas Pharmaceuticals Ltd
Lupin Ltd
Mycenax Biotech Inc
Myelo Therapeutics GmbH
Nohla Therapeutics Inc
Octapharma AG
Pangen Biotech Inc.
Pfenex Inc
Pfizer Inc
Reliance Life Sciences Pvt Ltd
Richter Gedeon Nyrt
Sandoz International GmbH
USV Pvt Ltd

レポート目次

---

1 Study Coverage
1.1 Chemotherapy Induced Neutropenia Drug Product Introduction
1.2 Market Segments
1.3 Key Chemotherapy Induced Neutropenia Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Chemotherapy Induced Neutropenia Drug Market Size Growth Rate by Type
1.4.2 F-627
1.4.3 BBT-018
1.4.4 Filgrastim
1.4.5 GW-003
1.4.6 NLA-101
1.4.7 Others
1.5 Market by Application
1.5.1 Global Chemotherapy Induced Neutropenia Drug Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Chemotherapy Induced Neutropenia Drug Market Size, Estimates and Forecasts
2.1.1 Global Chemotherapy Induced Neutropenia Drug Revenue 2015-2026
2.1.2 Global Chemotherapy Induced Neutropenia Drug Sales 2015-2026
2.2 Global Chemotherapy Induced Neutropenia Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Chemotherapy Induced Neutropenia Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Chemotherapy Induced Neutropenia Drug Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Chemotherapy Induced Neutropenia Drug Competitor Landscape by Players
3.1 Chemotherapy Induced Neutropenia Drug Sales by Manufacturers
3.1.1 Chemotherapy Induced Neutropenia Drug Sales by Manufacturers (2015-2020)
3.1.2 Chemotherapy Induced Neutropenia Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Chemotherapy Induced Neutropenia Drug Revenue by Manufacturers
3.2.1 Chemotherapy Induced Neutropenia Drug Revenue by Manufacturers (2015-2020)
3.2.2 Chemotherapy Induced Neutropenia Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Chemotherapy Induced Neutropenia Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Chemotherapy Induced Neutropenia Drug Revenue in 2019
3.2.5 Global Chemotherapy Induced Neutropenia Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Chemotherapy Induced Neutropenia Drug Price by Manufacturers
3.4 Chemotherapy Induced Neutropenia Drug Manufacturing Base Distribution, Product Types
3.4.1 Chemotherapy Induced Neutropenia Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Chemotherapy Induced Neutropenia Drug Product Type
3.4.3 Date of International Manufacturers Enter into Chemotherapy Induced Neutropenia Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Chemotherapy Induced Neutropenia Drug Market Size by Type (2015-2020)
4.1.1 Global Chemotherapy Induced Neutropenia Drug Sales by Type (2015-2020)
4.1.2 Global Chemotherapy Induced Neutropenia Drug Revenue by Type (2015-2020)
4.1.3 Chemotherapy Induced Neutropenia Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Chemotherapy Induced Neutropenia Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Chemotherapy Induced Neutropenia Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Chemotherapy Induced Neutropenia Drug Revenue Forecast by Type (2021-2026)
4.2.3 Chemotherapy Induced Neutropenia Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Chemotherapy Induced Neutropenia Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Chemotherapy Induced Neutropenia Drug Market Size by Application (2015-2020)
5.1.1 Global Chemotherapy Induced Neutropenia Drug Sales by Application (2015-2020)
5.1.2 Global Chemotherapy Induced Neutropenia Drug Revenue by Application (2015-2020)
5.1.3 Chemotherapy Induced Neutropenia Drug Price by Application (2015-2020)
5.2 Chemotherapy Induced Neutropenia Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Chemotherapy Induced Neutropenia Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Chemotherapy Induced Neutropenia Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Chemotherapy Induced Neutropenia Drug Price Forecast by Application (2021-2026)

6 North America
6.1 North America Chemotherapy Induced Neutropenia Drug by Country
6.1.1 North America Chemotherapy Induced Neutropenia Drug Sales by Country
6.1.2 North America Chemotherapy Induced Neutropenia Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Type
6.3 North America Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Application

7 Europe
7.1 Europe Chemotherapy Induced Neutropenia Drug by Country
7.1.1 Europe Chemotherapy Induced Neutropenia Drug Sales by Country
7.1.2 Europe Chemotherapy Induced Neutropenia Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Type
7.3 Europe Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Chemotherapy Induced Neutropenia Drug by Region
8.1.1 Asia Pacific Chemotherapy Induced Neutropenia Drug Sales by Region
8.1.2 Asia Pacific Chemotherapy Induced Neutropenia Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Type
8.3 Asia Pacific Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Application

9 Latin America
9.1 Latin America Chemotherapy Induced Neutropenia Drug by Country
9.1.1 Latin America Chemotherapy Induced Neutropenia Drug Sales by Country
9.1.2 Latin America Chemotherapy Induced Neutropenia Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Type
9.3 Central & South America Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Chemotherapy Induced Neutropenia Drug by Country
10.1.1 Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales by Country
10.1.2 Middle East and Africa Chemotherapy Induced Neutropenia Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Type
10.3 Middle East and Africa Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Application

11 Company Profiles
11.1 BeyondSpring Pharmaceuticals Inc
11.1.1 BeyondSpring Pharmaceuticals Inc Corporation Information
11.1.2 BeyondSpring Pharmaceuticals Inc Description and Business Overview
11.1.3 BeyondSpring Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 BeyondSpring Pharmaceuticals Inc Chemotherapy Induced Neutropenia Drug Products Offered
11.1.5 BeyondSpring Pharmaceuticals Inc Related Developments
11.2 Biocon Ltd
11.2.1 Biocon Ltd Corporation Information
11.2.2 Biocon Ltd Description and Business Overview
11.2.3 Biocon Ltd Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Biocon Ltd Chemotherapy Induced Neutropenia Drug Products Offered
11.2.5 Biocon Ltd Related Developments
11.3 Bolder Biotechnology Inc
11.3.1 Bolder Biotechnology Inc Corporation Information
11.3.2 Bolder Biotechnology Inc Description and Business Overview
11.3.3 Bolder Biotechnology Inc Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Bolder Biotechnology Inc Chemotherapy Induced Neutropenia Drug Products Offered
11.3.5 Bolder Biotechnology Inc Related Developments
11.4 Cellerant Therapeutics Inc
11.4.1 Cellerant Therapeutics Inc Corporation Information
11.4.2 Cellerant Therapeutics Inc Description and Business Overview
11.4.3 Cellerant Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Cellerant Therapeutics Inc Chemotherapy Induced Neutropenia Drug Products Offered
11.4.5 Cellerant Therapeutics Inc Related Developments
11.5 Chong Kun Dang Pharmaceutical Corp
11.5.1 Chong Kun Dang Pharmaceutical Corp Corporation Information
11.5.2 Chong Kun Dang Pharmaceutical Corp Description and Business Overview
11.5.3 Chong Kun Dang Pharmaceutical Corp Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Chong Kun Dang Pharmaceutical Corp Chemotherapy Induced Neutropenia Drug Products Offered
11.5.5 Chong Kun Dang Pharmaceutical Corp Related Developments
11.6 Cinfa Biotech SL
11.6.1 Cinfa Biotech SL Corporation Information
11.6.2 Cinfa Biotech SL Description and Business Overview
11.6.3 Cinfa Biotech SL Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Cinfa Biotech SL Chemotherapy Induced Neutropenia Drug Products Offered
11.6.5 Cinfa Biotech SL Related Developments
11.7 Dr. Reddy’s Laboratories Ltd
11.7.1 Dr. Reddy’s Laboratories Ltd Corporation Information
11.7.2 Dr. Reddy’s Laboratories Ltd Description and Business Overview
11.7.3 Dr. Reddy’s Laboratories Ltd Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Dr. Reddy’s Laboratories Ltd Chemotherapy Induced Neutropenia Drug Products Offered
11.7.5 Dr. Reddy’s Laboratories Ltd Related Developments
11.8 Gene Techno Science Co Ltd
11.8.1 Gene Techno Science Co Ltd Corporation Information
11.8.2 Gene Techno Science Co Ltd Description and Business Overview
11.8.3 Gene Techno Science Co Ltd Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Gene Techno Science Co Ltd Chemotherapy Induced Neutropenia Drug Products Offered
11.8.5 Gene Techno Science Co Ltd Related Developments
11.9 Generon (Shanghai) Corp Ltd
11.9.1 Generon (Shanghai) Corp Ltd Corporation Information
11.9.2 Generon (Shanghai) Corp Ltd Description and Business Overview
11.9.3 Generon (Shanghai) Corp Ltd Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Generon (Shanghai) Corp Ltd Chemotherapy Induced Neutropenia Drug Products Offered
11.9.5 Generon (Shanghai) Corp Ltd Related Developments
11.10 Genexine Inc
11.10.1 Genexine Inc Corporation Information
11.10.2 Genexine Inc Description and Business Overview
11.10.3 Genexine Inc Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Genexine Inc Chemotherapy Induced Neutropenia Drug Products Offered
11.10.5 Genexine Inc Related Developments
11.1 BeyondSpring Pharmaceuticals Inc
11.1.1 BeyondSpring Pharmaceuticals Inc Corporation Information
11.1.2 BeyondSpring Pharmaceuticals Inc Description and Business Overview
11.1.3 BeyondSpring Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 BeyondSpring Pharmaceuticals Inc Chemotherapy Induced Neutropenia Drug Products Offered
11.1.5 BeyondSpring Pharmaceuticals Inc Related Developments
11.12 Hanmi Pharmaceuticals Co Ltd
11.12.1 Hanmi Pharmaceuticals Co Ltd Corporation Information
11.12.2 Hanmi Pharmaceuticals Co Ltd Description and Business Overview
11.12.3 Hanmi Pharmaceuticals Co Ltd Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Hanmi Pharmaceuticals Co Ltd Products Offered
11.12.5 Hanmi Pharmaceuticals Co Ltd Related Developments
11.13 Intas Pharmaceuticals Ltd
11.13.1 Intas Pharmaceuticals Ltd Corporation Information
11.13.2 Intas Pharmaceuticals Ltd Description and Business Overview
11.13.3 Intas Pharmaceuticals Ltd Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Intas Pharmaceuticals Ltd Products Offered
11.13.5 Intas Pharmaceuticals Ltd Related Developments
11.14 Lupin Ltd
11.14.1 Lupin Ltd Corporation Information
11.14.2 Lupin Ltd Description and Business Overview
11.14.3 Lupin Ltd Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Lupin Ltd Products Offered
11.14.5 Lupin Ltd Related Developments
11.15 Mycenax Biotech Inc
11.15.1 Mycenax Biotech Inc Corporation Information
11.15.2 Mycenax Biotech Inc Description and Business Overview
11.15.3 Mycenax Biotech Inc Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Mycenax Biotech Inc Products Offered
11.15.5 Mycenax Biotech Inc Related Developments
11.16 Myelo Therapeutics GmbH
11.16.1 Myelo Therapeutics GmbH Corporation Information
11.16.2 Myelo Therapeutics GmbH Description and Business Overview
11.16.3 Myelo Therapeutics GmbH Sales, Revenue and Gross Margin (2015-2020)
11.16.4 Myelo Therapeutics GmbH Products Offered
11.16.5 Myelo Therapeutics GmbH Related Developments
11.17 Nohla Therapeutics Inc
11.17.1 Nohla Therapeutics Inc Corporation Information
11.17.2 Nohla Therapeutics Inc Description and Business Overview
11.17.3 Nohla Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.17.4 Nohla Therapeutics Inc Products Offered
11.17.5 Nohla Therapeutics Inc Related Developments
11.18 Octapharma AG
11.18.1 Octapharma AG Corporation Information
11.18.2 Octapharma AG Description and Business Overview
11.18.3 Octapharma AG Sales, Revenue and Gross Margin (2015-2020)
11.18.4 Octapharma AG Products Offered
11.18.5 Octapharma AG Related Developments
11.19 Pangen Biotech Inc.
11.19.1 Pangen Biotech Inc. Corporation Information
11.19.2 Pangen Biotech Inc. Description and Business Overview
11.19.3 Pangen Biotech Inc. Sales, Revenue and Gross Margin (2015-2020)
11.19.4 Pangen Biotech Inc. Products Offered
11.19.5 Pangen Biotech Inc. Related Developments
11.20 Pfenex Inc
11.20.1 Pfenex Inc Corporation Information
11.20.2 Pfenex Inc Description and Business Overview
11.20.3 Pfenex Inc Sales, Revenue and Gross Margin (2015-2020)
11.20.4 Pfenex Inc Products Offered
11.20.5 Pfenex Inc Related Developments
11.21 Pfizer Inc
11.21.1 Pfizer Inc Corporation Information
11.21.2 Pfizer Inc Description and Business Overview
11.21.3 Pfizer Inc Sales, Revenue and Gross Margin (2015-2020)
11.21.4 Pfizer Inc Products Offered
11.21.5 Pfizer Inc Related Developments
11.22 Reliance Life Sciences Pvt Ltd
11.22.1 Reliance Life Sciences Pvt Ltd Corporation Information
11.22.2 Reliance Life Sciences Pvt Ltd Description and Business Overview
11.22.3 Reliance Life Sciences Pvt Ltd Sales, Revenue and Gross Margin (2015-2020)
11.22.4 Reliance Life Sciences Pvt Ltd Products Offered
11.22.5 Reliance Life Sciences Pvt Ltd Related Developments
11.23 Richter Gedeon Nyrt
11.23.1 Richter Gedeon Nyrt Corporation Information
11.23.2 Richter Gedeon Nyrt Description and Business Overview
11.23.3 Richter Gedeon Nyrt Sales, Revenue and Gross Margin (2015-2020)
11.23.4 Richter Gedeon Nyrt Products Offered
11.23.5 Richter Gedeon Nyrt Related Developments
11.24 Sandoz International GmbH
11.24.1 Sandoz International GmbH Corporation Information
11.24.2 Sandoz International GmbH Description and Business Overview
11.24.3 Sandoz International GmbH Sales, Revenue and Gross Margin (2015-2020)
11.24.4 Sandoz International GmbH Products Offered
11.24.5 Sandoz International GmbH Related Developments
11.25 USV Pvt Ltd
11.25.1 USV Pvt Ltd Corporation Information
11.25.2 USV Pvt Ltd Description and Business Overview
11.25.3 USV Pvt Ltd Sales, Revenue and Gross Margin (2015-2020)
11.25.4 USV Pvt Ltd Products Offered
11.25.5 USV Pvt Ltd Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Chemotherapy Induced Neutropenia Drug Market Estimates and Projections by Region
12.1.1 Global Chemotherapy Induced Neutropenia Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Chemotherapy Induced Neutropenia Drug Revenue Forecast by Regions 2021-2026
12.2 North America Chemotherapy Induced Neutropenia Drug Market Size Forecast (2021-2026)
12.2.1 North America: Chemotherapy Induced Neutropenia Drug Sales Forecast (2021-2026)
12.2.2 North America: Chemotherapy Induced Neutropenia Drug Revenue Forecast (2021-2026)
12.2.3 North America: Chemotherapy Induced Neutropenia Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Chemotherapy Induced Neutropenia Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Chemotherapy Induced Neutropenia Drug Sales Forecast (2021-2026)
12.3.2 Europe: Chemotherapy Induced Neutropenia Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Chemotherapy Induced Neutropenia Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Chemotherapy Induced Neutropenia Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Chemotherapy Induced Neutropenia Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Chemotherapy Induced Neutropenia Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Chemotherapy Induced Neutropenia Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Chemotherapy Induced Neutropenia Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Chemotherapy Induced Neutropenia Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Chemotherapy Induced Neutropenia Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Chemotherapy Induced Neutropenia Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Chemotherapy Induced Neutropenia Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Chemotherapy Induced Neutropenia Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Chemotherapy Induced Neutropenia Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Chemotherapy Induced Neutropenia Drug Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Chemotherapy Induced Neutropenia Drug Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Chemotherapy Induced Neutropenia Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Chemotherapy Induced Neutropenia Drug Market Segments
Table 2. Ranking of Global Top Chemotherapy Induced Neutropenia Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Chemotherapy Induced Neutropenia Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of F-627
Table 5. Major Manufacturers of BBT-018
Table 6. Major Manufacturers of Filgrastim
Table 7. Major Manufacturers of GW-003
Table 8. Major Manufacturers of NLA-101
Table 9. Major Manufacturers of Others
Table 10. Global Chemotherapy Induced Neutropenia Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 11. Global Chemotherapy Induced Neutropenia Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 12. Global Chemotherapy Induced Neutropenia Drug Sales by Regions 2015-2020 (K Pcs)
Table 13. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Regions (2015-2020)
Table 14. Global Chemotherapy Induced Neutropenia Drug Revenue by Regions 2015-2020 (US$ Million)
Table 15. Global Chemotherapy Induced Neutropenia Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 16. Global Chemotherapy Induced Neutropenia Drug Sales Share by Manufacturers (2015-2020)
Table 17. Global Chemotherapy Induced Neutropenia Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 18. Global Chemotherapy Induced Neutropenia Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chemotherapy Induced Neutropenia Drug as of 2019)
Table 19. Chemotherapy Induced Neutropenia Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 20. Chemotherapy Induced Neutropenia Drug Revenue Share by Manufacturers (2015-2020)
Table 21. Key Manufacturers Chemotherapy Induced Neutropenia Drug Price (2015-2020) (USD/Pcs)
Table 22. Chemotherapy Induced Neutropenia Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Chemotherapy Induced Neutropenia Drug Product Type
Table 24. Date of International Manufacturers Enter into Chemotherapy Induced Neutropenia Drug Market
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Global Chemotherapy Induced Neutropenia Drug Sales by Type (2015-2020) (K Pcs)
Table 27. Global Chemotherapy Induced Neutropenia Drug Sales Share by Type (2015-2020)
Table 28. Global Chemotherapy Induced Neutropenia Drug Revenue by Type (2015-2020) (US$ Million)
Table 29. Global Chemotherapy Induced Neutropenia Drug Revenue Share by Type (2015-2020)
Table 30. Chemotherapy Induced Neutropenia Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 31. Global Chemotherapy Induced Neutropenia Drug Sales by Application (2015-2020) (K Pcs)
Table 32. Global Chemotherapy Induced Neutropenia Drug Sales Share by Application (2015-2020)
Table 33. North America Chemotherapy Induced Neutropenia Drug Sales by Country (2015-2020) (K Pcs)
Table 34. North America Chemotherapy Induced Neutropenia Drug Sales Market Share by Country (2015-2020)
Table 35. North America Chemotherapy Induced Neutropenia Drug Revenue by Country (2015-2020) (US$ Million)
Table 36. North America Chemotherapy Induced Neutropenia Drug Revenue Market Share by Country (2015-2020)
Table 37. North America Chemotherapy Induced Neutropenia Drug Sales by Type (2015-2020) (K Pcs)
Table 38. North America Chemotherapy Induced Neutropenia Drug Sales Market Share by Type (2015-2020)
Table 39. North America Chemotherapy Induced Neutropenia Drug Sales by Application (2015-2020) (K Pcs)
Table 40. North America Chemotherapy Induced Neutropenia Drug Sales Market Share by Application (2015-2020)
Table 41. Europe Chemotherapy Induced Neutropenia Drug Sales by Country (2015-2020) (K Pcs)
Table 42. Europe Chemotherapy Induced Neutropenia Drug Sales Market Share by Country (2015-2020)
Table 43. Europe Chemotherapy Induced Neutropenia Drug Revenue by Country (2015-2020) (US$ Million)
Table 44. Europe Chemotherapy Induced Neutropenia Drug Revenue Market Share by Country (2015-2020)
Table 45. Europe Chemotherapy Induced Neutropenia Drug Sales by Type (2015-2020) (K Pcs)
Table 46. Europe Chemotherapy Induced Neutropenia Drug Sales Market Share by Type (2015-2020)
Table 47. Europe Chemotherapy Induced Neutropenia Drug Sales by Application (2015-2020) (K Pcs)
Table 48. Europe Chemotherapy Induced Neutropenia Drug Sales Market Share by Application (2015-2020)
Table 49. Asia Pacific Chemotherapy Induced Neutropenia Drug Sales by Region (2015-2020) (K Pcs)
Table 50. Asia Pacific Chemotherapy Induced Neutropenia Drug Sales Market Share by Region (2015-2020)
Table 51. Asia Pacific Chemotherapy Induced Neutropenia Drug Revenue by Region (2015-2020) (US$ Million)
Table 52. Asia Pacific Chemotherapy Induced Neutropenia Drug Revenue Market Share by Region (2015-2020)
Table 53. Asia Pacific Chemotherapy Induced Neutropenia Drug Sales by Type (2015-2020) (K Pcs)
Table 54. Asia Pacific Chemotherapy Induced Neutropenia Drug Sales Market Share by Type (2015-2020)
Table 55. Asia Pacific Chemotherapy Induced Neutropenia Drug Sales by Application (2015-2020) (K Pcs)
Table 56. Asia Pacific Chemotherapy Induced Neutropenia Drug Sales Market Share by Application (2015-2020)
Table 57. Latin America Chemotherapy Induced Neutropenia Drug Sales by Country (2015-2020) (K Pcs)
Table 58. Latin America Chemotherapy Induced Neutropenia Drug Sales Market Share by Country (2015-2020)
Table 59. Latin Americaa Chemotherapy Induced Neutropenia Drug Revenue by Country (2015-2020) (US$ Million)
Table 60. Latin America Chemotherapy Induced Neutropenia Drug Revenue Market Share by Country (2015-2020)
Table 61. Latin America Chemotherapy Induced Neutropenia Drug Sales by Type (2015-2020) (K Pcs)
Table 62. Latin America Chemotherapy Induced Neutropenia Drug Sales Market Share by Type (2015-2020)
Table 63. Latin America Chemotherapy Induced Neutropenia Drug Sales by Application (2015-2020) (K Pcs)
Table 64. Latin America Chemotherapy Induced Neutropenia Drug Sales Market Share by Application (2015-2020)
Table 65. Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales by Country (2015-2020) (K Pcs)
Table 66. Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales Market Share by Country (2015-2020)
Table 67. Middle East and Africa Chemotherapy Induced Neutropenia Drug Revenue by Country (2015-2020) (US$ Million)
Table 68. Middle East and Africa Chemotherapy Induced Neutropenia Drug Revenue Market Share by Country (2015-2020)
Table 69. Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales by Type (2015-2020) (K Pcs)
Table 70. Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales Market Share by Type (2015-2020)
Table 71. Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales by Application (2015-2020) (K Pcs)
Table 72. Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales Market Share by Application (2015-2020)
Table 73. BeyondSpring Pharmaceuticals Inc Corporation Information
Table 74. BeyondSpring Pharmaceuticals Inc Description and Major Businesses
Table 75. BeyondSpring Pharmaceuticals Inc Chemotherapy Induced Neutropenia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 76. BeyondSpring Pharmaceuticals Inc Product
Table 77. BeyondSpring Pharmaceuticals Inc Recent Development
Table 78. Biocon Ltd Corporation Information
Table 79. Biocon Ltd Description and Major Businesses
Table 80. Biocon Ltd Chemotherapy Induced Neutropenia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 81. Biocon Ltd Product
Table 82. Biocon Ltd Recent Development
Table 83. Bolder Biotechnology Inc Corporation Information
Table 84. Bolder Biotechnology Inc Description and Major Businesses
Table 85. Bolder Biotechnology Inc Chemotherapy Induced Neutropenia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 86. Bolder Biotechnology Inc Product
Table 87. Bolder Biotechnology Inc Recent Development
Table 88. Cellerant Therapeutics Inc Corporation Information
Table 89. Cellerant Therapeutics Inc Description and Major Businesses
Table 90. Cellerant Therapeutics Inc Chemotherapy Induced Neutropenia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 91. Cellerant Therapeutics Inc Product
Table 92. Cellerant Therapeutics Inc Recent Development
Table 93. Chong Kun Dang Pharmaceutical Corp Corporation Information
Table 94. Chong Kun Dang Pharmaceutical Corp Description and Major Businesses
Table 95. Chong Kun Dang Pharmaceutical Corp Chemotherapy Induced Neutropenia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 96. Chong Kun Dang Pharmaceutical Corp Product
Table 97. Chong Kun Dang Pharmaceutical Corp Recent Development
Table 98. Cinfa Biotech SL Corporation Information
Table 99. Cinfa Biotech SL Description and Major Businesses
Table 100. Cinfa Biotech SL Chemotherapy Induced Neutropenia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 101. Cinfa Biotech SL Product
Table 102. Cinfa Biotech SL Recent Development
Table 103. Dr. Reddy's Laboratories Ltd Corporation Information
Table 104. Dr. Reddy's Laboratories Ltd Description and Major Businesses
Table 105. Dr. Reddy's Laboratories Ltd Chemotherapy Induced Neutropenia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 106. Dr. Reddy's Laboratories Ltd Product
Table 107. Dr. Reddy's Laboratories Ltd Recent Development
Table 108. Gene Techno Science Co Ltd Corporation Information
Table 109. Gene Techno Science Co Ltd Description and Major Businesses
Table 110. Gene Techno Science Co Ltd Chemotherapy Induced Neutropenia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 111. Gene Techno Science Co Ltd Product
Table 112. Gene Techno Science Co Ltd Recent Development
Table 113. Generon (Shanghai) Corp Ltd Corporation Information
Table 114. Generon (Shanghai) Corp Ltd Description and Major Businesses
Table 115. Generon (Shanghai) Corp Ltd Chemotherapy Induced Neutropenia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 116. Generon (Shanghai) Corp Ltd Product
Table 117. Generon (Shanghai) Corp Ltd Recent Development
Table 118. Genexine Inc Corporation Information
Table 119. Genexine Inc Description and Major Businesses
Table 120. Genexine Inc Chemotherapy Induced Neutropenia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 121. Genexine Inc Product
Table 122. Genexine Inc Recent Development
Table 123. GlycoMimetics Inc Corporation Information
Table 124. GlycoMimetics Inc Description and Major Businesses
Table 125. GlycoMimetics Inc Chemotherapy Induced Neutropenia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 126. GlycoMimetics Inc Product
Table 127. GlycoMimetics Inc Recent Development
Table 128. Hanmi Pharmaceuticals Co Ltd Corporation Information
Table 129. Hanmi Pharmaceuticals Co Ltd Description and Major Businesses
Table 130. Hanmi Pharmaceuticals Co Ltd Chemotherapy Induced Neutropenia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 131. Hanmi Pharmaceuticals Co Ltd Product
Table 132. Hanmi Pharmaceuticals Co Ltd Recent Development
Table 133. Intas Pharmaceuticals Ltd Corporation Information
Table 134. Intas Pharmaceuticals Ltd Description and Major Businesses
Table 135. Intas Pharmaceuticals Ltd Chemotherapy Induced Neutropenia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 136. Intas Pharmaceuticals Ltd Product
Table 137. Intas Pharmaceuticals Ltd Recent Development
Table 138. Lupin Ltd Corporation Information
Table 139. Lupin Ltd Description and Major Businesses
Table 140. Lupin Ltd Chemotherapy Induced Neutropenia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 141. Lupin Ltd Product
Table 142. Lupin Ltd Recent Development
Table 143. Mycenax Biotech Inc Corporation Information
Table 144. Mycenax Biotech Inc Description and Major Businesses
Table 145. Mycenax Biotech Inc Chemotherapy Induced Neutropenia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 146. Mycenax Biotech Inc Product
Table 147. Mycenax Biotech Inc Recent Development
Table 148. Myelo Therapeutics GmbH Corporation Information
Table 149. Myelo Therapeutics GmbH Description and Major Businesses
Table 150. Myelo Therapeutics GmbH Chemotherapy Induced Neutropenia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 151. Myelo Therapeutics GmbH Product
Table 152. Myelo Therapeutics GmbH Recent Development
Table 153. Nohla Therapeutics Inc Corporation Information
Table 154. Nohla Therapeutics Inc Description and Major Businesses
Table 155. Nohla Therapeutics Inc Chemotherapy Induced Neutropenia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 156. Nohla Therapeutics Inc Product
Table 157. Nohla Therapeutics Inc Recent Development
Table 158. Octapharma AG Corporation Information
Table 159. Octapharma AG Description and Major Businesses
Table 160. Octapharma AG Chemotherapy Induced Neutropenia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 161. Octapharma AG Product
Table 162. Octapharma AG Recent Development
Table 163. Pangen Biotech Inc. Corporation Information
Table 164. Pangen Biotech Inc. Description and Major Businesses
Table 165. Pangen Biotech Inc. Chemotherapy Induced Neutropenia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 166. Pangen Biotech Inc. Product
Table 167. Pangen Biotech Inc. Recent Development
Table 168. Pfenex Inc Corporation Information
Table 169. Pfenex Inc Description and Major Businesses
Table 170. Pfenex Inc Chemotherapy Induced Neutropenia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 171. Pfenex Inc Product
Table 172. Pfenex Inc Recent Development
Table 173. Pfizer Inc Corporation Information
Table 174. Pfizer Inc Description and Major Businesses
Table 175. Pfizer Inc Chemotherapy Induced Neutropenia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 176. Pfizer Inc Product
Table 177. Pfizer Inc Recent Development
Table 178. Reliance Life Sciences Pvt Ltd Corporation Information
Table 179. Reliance Life Sciences Pvt Ltd Description and Major Businesses
Table 180. Reliance Life Sciences Pvt Ltd Chemotherapy Induced Neutropenia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 181. Reliance Life Sciences Pvt Ltd Product
Table 182. Reliance Life Sciences Pvt Ltd Recent Development
Table 183. Richter Gedeon Nyrt Corporation Information
Table 184. Richter Gedeon Nyrt Description and Major Businesses
Table 185. Richter Gedeon Nyrt Chemotherapy Induced Neutropenia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 186. Richter Gedeon Nyrt Product
Table 187. Richter Gedeon Nyrt Recent Development
Table 188. Sandoz International GmbH Corporation Information
Table 189. Sandoz International GmbH Description and Major Businesses
Table 190. Sandoz International GmbH Chemotherapy Induced Neutropenia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 191. Sandoz International GmbH Product
Table 192. Sandoz International GmbH Recent Development
Table 193. USV Pvt Ltd Corporation Information
Table 194. USV Pvt Ltd Description and Major Businesses
Table 195. USV Pvt Ltd Chemotherapy Induced Neutropenia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 196. USV Pvt Ltd Product
Table 197. USV Pvt Ltd Recent Development
Table 198. Global Chemotherapy Induced Neutropenia Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 199. Global Chemotherapy Induced Neutropenia Drug Sales Market Share Forecast by Regions (2021-2026)
Table 200. Global Chemotherapy Induced Neutropenia Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 201. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 202. North America: Chemotherapy Induced Neutropenia Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 203. North America: Chemotherapy Induced Neutropenia Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 204. Europe: Chemotherapy Induced Neutropenia Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 205. Europe: Chemotherapy Induced Neutropenia Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 206. Asia Pacific: Chemotherapy Induced Neutropenia Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 207. Asia Pacific: Chemotherapy Induced Neutropenia Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 208. Latin America: Chemotherapy Induced Neutropenia Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 209. Latin America: Chemotherapy Induced Neutropenia Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 210. Middle East and Africa: Chemotherapy Induced Neutropenia Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 211. Middle East and Africa: Chemotherapy Induced Neutropenia Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 212. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 213. Key Challenges
Table 214. Market Risks
Table 215. Main Points Interviewed from Key Chemotherapy Induced Neutropenia Drug Players
Table 216. Chemotherapy Induced Neutropenia Drug Customers List
Table 217. Chemotherapy Induced Neutropenia Drug Distributors List
Table 218. Research Programs/Design for This Report
Table 219. Key Data Information from Secondary Sources
Table 220. Key Data Information from Primary Sources
List of Figures
Figure 1. Chemotherapy Induced Neutropenia Drug Product Picture
Figure 2. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Type in 2020 & 2026
Figure 3. F-627 Product Picture
Figure 4. BBT-018 Product Picture
Figure 5. Filgrastim Product Picture
Figure 6. GW-003 Product Picture
Figure 7. NLA-101 Product Picture
Figure 8. Others Product Picture
Figure 9. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Application in 2020 & 2026
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Chemotherapy Induced Neutropenia Drug Report Years Considered
Figure 14. Global Chemotherapy Induced Neutropenia Drug Market Size 2015-2026 (US$ Million)
Figure 15. Global Chemotherapy Induced Neutropenia Drug Sales 2015-2026 (K Pcs)
Figure 16. Global Chemotherapy Induced Neutropenia Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 17. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Region (2015-2020)
Figure 18. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Region in 2019
Figure 19. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Region (2015-2020)
Figure 20. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Region in 2019
Figure 21. Global Chemotherapy Induced Neutropenia Drug Sales Share by Manufacturer in 2019
Figure 22. The Top 10 and 5 Players Market Share by Chemotherapy Induced Neutropenia Drug Revenue in 2019
Figure 23. Chemotherapy Induced Neutropenia Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 24. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Type (2015-2020)
Figure 25. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Type in 2019
Figure 26. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Type (2015-2020)
Figure 27. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Type in 2019
Figure 28. Global Chemotherapy Induced Neutropenia Drug Market Share by Price Range (2015-2020)
Figure 29. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Application (2015-2020)
Figure 30. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Application in 2019
Figure 31. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Application (2015-2020)
Figure 32. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Application in 2019
Figure 33. North America Chemotherapy Induced Neutropenia Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 34. North America Chemotherapy Induced Neutropenia Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 35. North America Chemotherapy Induced Neutropenia Drug Sales Market Share by Country in 2019
Figure 36. North America Chemotherapy Induced Neutropenia Drug Revenue Market Share by Country in 2019
Figure 37. U.S. Chemotherapy Induced Neutropenia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 38. U.S. Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. Canada Chemotherapy Induced Neutropenia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 40. Canada Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. North America Chemotherapy Induced Neutropenia Drug Market Share by Type in 2019
Figure 42. North America Chemotherapy Induced Neutropenia Drug Market Share by Application in 2019
Figure 43. Europe Chemotherapy Induced Neutropenia Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 44. Europe Chemotherapy Induced Neutropenia Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 45. Europe Chemotherapy Induced Neutropenia Drug Sales Market Share by Country in 2019
Figure 46. Europe Chemotherapy Induced Neutropenia Drug Revenue Market Share by Country in 2019
Figure 47. Germany Chemotherapy Induced Neutropenia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. Germany Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. France Chemotherapy Induced Neutropenia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 50. France Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. U.K. Chemotherapy Induced Neutropenia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. U.K. Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Italy Chemotherapy Induced Neutropenia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. Italy Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Russia Chemotherapy Induced Neutropenia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 56. Russia Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Europe Chemotherapy Induced Neutropenia Drug Market Share by Type in 2019
Figure 58. Europe Chemotherapy Induced Neutropenia Drug Market Share by Application in 2019
Figure 59. Asia Pacific Chemotherapy Induced Neutropenia Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 60. Asia Pacific Chemotherapy Induced Neutropenia Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 61. Asia Pacific Chemotherapy Induced Neutropenia Drug Sales Market Share by Region in 2019
Figure 62. Asia Pacific Chemotherapy Induced Neutropenia Drug Revenue Market Share by Region in 2019
Figure 63. China Chemotherapy Induced Neutropenia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 64. China Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. Japan Chemotherapy Induced Neutropenia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 66. Japan Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. South Korea Chemotherapy Induced Neutropenia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. South Korea Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. India Chemotherapy Induced Neutropenia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. India Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Australia Chemotherapy Induced Neutropenia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. Australia Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Taiwan Chemotherapy Induced Neutropenia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. Taiwan Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Indonesia Chemotherapy Induced Neutropenia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Indonesia Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Thailand Chemotherapy Induced Neutropenia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Thailand Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Malaysia Chemotherapy Induced Neutropenia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Malaysia Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Philippines Chemotherapy Induced Neutropenia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Philippines Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Vietnam Chemotherapy Induced Neutropenia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 84. Vietnam Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Asia Pacific Chemotherapy Induced Neutropenia Drug Market Share by Type in 2019
Figure 86. Asia Pacific Chemotherapy Induced Neutropenia Drug Market Share by Application in 2019
Figure 87. Latin America Chemotherapy Induced Neutropenia Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 88. Latin America Chemotherapy Induced Neutropenia Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 89. Latin America Chemotherapy Induced Neutropenia Drug Sales Market Share by Country in 2019
Figure 90. Latin America Chemotherapy Induced Neutropenia Drug Revenue Market Share by Country in 2019
Figure 91. Mexico Chemotherapy Induced Neutropenia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 92. Mexico Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Brazil Chemotherapy Induced Neutropenia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 94. Brazil Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Argentina Chemotherapy Induced Neutropenia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 96. Argentina Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Latin America Chemotherapy Induced Neutropenia Drug Market Share by Type in 2019
Figure 98. Latin America Chemotherapy Induced Neutropenia Drug Market Share by Application in 2019
Figure 99. Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 100. Middle East and Africa Chemotherapy Induced Neutropenia Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 101. Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales Market Share by Country in 2019
Figure 102. Middle East and Africa Chemotherapy Induced Neutropenia Drug Revenue Market Share by Country in 2019
Figure 103. Turkey Chemotherapy Induced Neutropenia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 104. Turkey Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Saudi Arabia Chemotherapy Induced Neutropenia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 106. Saudi Arabia Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. U.A.E Chemotherapy Induced Neutropenia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 108. U.A.E Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. Middle East and Africa Chemotherapy Induced Neutropenia Drug Market Share by Type in 2019
Figure 110. Middle East and Africa Chemotherapy Induced Neutropenia Drug Market Share by Application in 2019
Figure 111. North America Chemotherapy Induced Neutropenia Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 112. North America Chemotherapy Induced Neutropenia Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Europe Chemotherapy Induced Neutropenia Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 114. Europe Chemotherapy Induced Neutropenia Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Asia Pacific Chemotherapy Induced Neutropenia Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figu

---